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Abstract
Background: Carbohydrate  antigen  (CA)19-9  that  is  the  most widely used biomarker for pancreatic cancer has certain 
limitations in diagnosis, which results in a tough job to distinguish pancreatic cancer from benign tumors with normal CA19-
9. The aim of  this study was to investigate the diagnostic utility of  clinical parameters and serum markers in patients with 
pancreatic head masses  but without elevated  CA19-9.
Methods: Retrospectively, 106 (69 malignant, 37 benign) of  487 patients admitted for pancreatic head masses were enrolled 
with CA19-9 level of  <37u/ml. Clinical parameters and serum biomarkers were assessed.  Among the patients with pan-
creatic head mass, male individuals (p=0.025) and elder individuals (p<0.001) were more likely to have cancer;  and cancer 
patients were more likely to present with abdominal-pain (p=0.023), weight-loss (p=0.013) and jaundice (p<0.001). Serum 
bilirubin levels among malignancies,  including total bilirubin (p<0.001), direct bilirubin (p<0.001) and indirect bilirubin 
(p<0.001),  were considerably higher  than  those  of   benign  ones.  Logistic  regression  further concluded  that  age-dis-
tribution,  abdominal-pain  and  direct-bilirubin  were  three independent factors correlating with final diagnosis. However, 
CEA (p=0.156) was not sufficient enough to exclude pancreatic cancer.
Conclusions: In patients with pancreatic head masses and CA19-9 of  <37u/ml, age-distribution, abdominal-pain and direct 
bilirubin might be helpful in differential diagnosis. CEA was insufficient for exclusion of  malignancy.
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Pancreatic  cancer  is  one of   the  most  lethal  malig-
nant tumors,  with a 5-year survival of  less than 0.4% to 
5% 1-3. Only 20% of  patients are considered eligible for 
surgery at the time of  diagnosis, and only half  of  them 
are suitsble for curative resection1.  The  most  benefi-
cial  treatment  of   this  disease  is  complete  surgical 
resection in its early stage. Therefore, early and accurate 
diagnosis of  patients with a suspicious pancreatic mass 
is  critical. However, it is difficult to preoperatively dis-
tinguish malignancies from benign tumors with cur-
rently available diagnostic modalities at an early stage.
At  present,  clinical  diagnosis  depends   mainly  on 
a  variety  of    imaging technologies and a single serum 
carbohydrate antigen(CA)19-9 level2-5. Serum CA19-9 
has a reported sensitivity of  70% to 90%, specificity of  
approximately 90%, positive predictive value of   about 
69%, and negative predictive value of   about 90% in 
screening for pancreatic carcinoma6. However, elevated 
CA19-9 levels  have also  been  found  in  several  benign 
diseases,  including  chronic/acute  pancreatitis, cholan-
gitis, and lymphoepithelial cyst of  the pancreas2,7,8. In 
addition, CA19-9 could not be detected in subjects with 
Lewis a-b- genotype9. Furthermore, only about 50% 
of  patients with pancreatic carcinomas of  <3cm had 
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elevated CA19-9 levels, and poorly differentiated ma-
lignant tumors secreted lower concentrations of  CA19-
9 than medium/well- differentiated ones did10. Given 
these limitations, malignant carriers with normal CA19-
9 levels but positive imaging findings would appear 
even more difficult in distinguishing from benign ones.
Approximately 70% to 80% of  patients with pancreat-
ic cancer, mostly located in pancreatic head, presented 
with obstructive jaundice11, and in some studies carc-
inoembryonic antigen (CEA) was proven to increase 
diagnostic accuracy of  pancreatic cancer12,13. Therefore, 
serum bilirubin and CEA levels may serve as helpful 
complements  to  imaging     and  single  CA19-9  meas-
urement.  Since  the correlation between those param-
eters  (both biochemical markers   and clinical  char-
acteristics) and pancreatic head cancer haven’t clearly 
been defined yet, the aim of  this study was to assess 
the utility of  these factors in diagnosis of  pancreatic 
malignancies with imaging evidence and normal CA19-
9 levels.
Material and methods
Details of  all referrals with a pancreatic head mass 
that was proven by instrumental examinations before 
medical intervention were retrospectively collected and 
maintained  in  an  original  database.  Instrumental  ex-
aminations  consisted  of  computed tomography (CT), 
magnetic resonance imaging (MRI), ultrasonography, 
and endoscopic retrograde cholangiopancreatography 
(ERCP). Complete data was taken  with the permission 
of  the hospital from the records of  all patients admit-
ted to the Department of  Surgery, Second Affiliated 
hospital, College of  Medicine, Zhejiang University  be-
tween  January  2003  and  December  2009.  Clinical 
database  was explored with the permission of  the hos-
pital. The clinical decision of  malignancy or benign was 
determined by final pathological diagnosis, which was 
based on results of  operative biopsies, endoscopic bi-
opsies, or surgical specimens. Patients among the orig-
inal database with serum CA19-9 levels of  <37u/ml, 
which was recommended in most literature as normal 
level2,6,14,15, were enrolled for further study. Patients lack-
ing imaging support or pathological diagnosis as well as 
patients with metastasis were excluded. Patients without 
complete medical records were also eliminated.
With informed consent,all  patients  enrolled  for  fur-
ther  study  underwent complete standard blood exam-
inations, including serum bilirubin (total bilirubin(TB),
direct bilirubin(DB) and indirect bilirubin(IB)), CA19-
9, and CEA levels. Clinical symptoms that might appear 
during the development of  diseases included abdomi-
nal pain,  back  pain,  weight  loss, fever,  and  jaundice. 
The  CA19-9  cutoff  value  was described  above  as 
37u/ml.  Patients  with  serum  TB  levels  of   >2mg/
dl  were considered   to   be   jaundiced   according   to 
the   testing   reagent   manufacturer’s specification for 
the reference range. All blood tests were performed by 
our clinical laboratory using the  same  manufacturer’s 
specified  testing reagents  and  standard testing proce-
dure.
Statistic  analysis  was  performed  with  SPSS  16.0  for 
Windows  (SPSS,  Inc., Chicago, IL, US), and statisti-
cal significance was accepted at the p<0.05 level. Non-
parametric  tests were preferred when data distribution 
was   not   certain. Comparison of  serum marker lev-
els between the malignant and benign groups were ob-
tained with the Mann–Whitney U test. Differences in 
frequencies for categorical variables were assessed by 
chi-square test. Multivariable analysis for detecting pan-
creatic head cancer was carried out using binary logistic 
regression. To further estimate the diagnostic abilities, 
receiver operating characteristics (ROC) curves were 
built. The   area under  the  curve (AUC) was  calculated 
for  assessment  of  malignancy-detecting ability.
Results
Data of  487 patients was recorded in the original da-
tabase at the beginning of  the study. According to the 
aforementioned criteria, 106 patients with CA19-9 lev-
els of  <37 u/ml were finally enrolled. Pathological di-
agnosis proved that 69 (65.09%) of  these 106 patients 
carried malignant tumors (Group 1), and the remaining 
37 (34.91%) carried  benign  ones  (Group  2).  Clinical 
parameters  and  serum  biomarkers  were summarized 
in Table 1. 
In group 1, 68 patients had pancreatic ductal adenocar-





Malignant (%)      Benign (%)              P
Male 40 (57.97) 13 (35.14)  
Female 29 (42.03) 24 (64.86) 0.025 
Age 61.65±11.77 49.84±16.16 < 0.001 
Abdominal pain 44 (63.77) 17 (45.95) 0.023 
Back pain 12 (17.39) 5 (13.51) 0.604 
Weight loss 20 (28.99) 3 (8.11) 0.013 
Fever 4 (5.80) 0 (0.00) 0.295 
Jaundice 29 (42.03) 1 (2.70) < 0.001 
Pathology    
Ductal adenocarcinoma 68 (98.55)   
Mucinous cystadenocarcinoma 1 (1.45)   
Mucinous cystadenoma  9 (24.32)  
Chronic pancreatitis  7 (18.92)  
Solid pseudopapillary tumor  6 (16.22)  
Insulinoma  6 (16.22)  
Serous cystadenoma  5 (13.51)  
Intraductal papillary mucinous 
tumor 
 4 (10.81)  
Common bile duct (cm) 1.00±0.49 0.73±0.30 0.002 
Tumor size (cm) 4.54±2.60 4.34±2.77 0.599 
Total bilirubin (mg/dl) 5.46±14.43 0.71±0.51 < 0.001 












CA19-92 (u/ml) 13.16±9.45 10.39±7.63 0.154 
 
Gender
1: CEA equals Carcinoembryonic antigen.
2: CA19-9 equals Carbohydrate antigen19-9
cinoma and the remaining one had mucinous cystade-
nocarcinoma. Among group 2, eight had mucinouscys-
tadenoma,    seven    had    chronic    pancreatitis,    seven 
had    solid- pseudopapillary tumor, six had insulinoma, 
five had serous cystadenoma and four had intraductal 
papillary mucinous tumor. group 1 was comprised of  
40 men and 29 women with a median age of  62 years 
(range, 30–82 years), while group 2 consisted of  13 men 
and 24 women with a median age of  53 years (range, 
16–80 years) (Table 1). In group 1, 44 (63.77%) patients 
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suffered from abdominal pain and 12 (17.39%) suffered 
from back pain. In group 2, 17 (45.95%) patients ex-
perienced abdominal pain and 5 (13.51%) experienced 
back pain. Twenty of  69 (28.99%) and 3 of  37 (8.11%) 
patients underwent weight loss. Only 4 of  the total 106 
people developed a fever,  and  they  were  all  can-
cer patients  (Table 1).  Besides sex ratio (p=0.025) and 
age distribution (p<0.001), abdominal-pain (p=0.023), 
weight-loss (p=0.013) and jaundice (p<0.001) were also 
statistically different in two groups; while back-pain 
(p=0.604) and fever (p=0.295) were not (Table 1).
The serum total bilirubin (TB) level in group 1(median, 
1.27; range, 0.18–116.10 mg/dl) was significantly higher 
than that of  group 2 (median, 0.64; range, 0.17–3.14 
mg/dl) (p<0.001), and the same results were observed 
when direct and indirect bilirubin levels were compared 
between two groups (both p<0.001) (Table 1). To as-
sess the severity of  obstruction in the common bile 
duct (CBD), which resulted from the pancreatic head 
mass  and  gave  rise  to high  hyperbilirubinemia  (es-
pecially direct bilirubin), the tumor size and diameter 
of  the CBD in both groups were measured according 
to the screenage data. However, although no difference 
(p=0.599) was found in tumor size(benign median, 
3.65; range, 1.60–15.50 cm versus malignant median, 
4.00; range, 1.30–13.00 cm) between 2 groups, statis-
tical significance was obtained in the dilation of  CBD 
(benign median, 0.60; range, 0.60–1.70 cm versus ma-
lignant median, 0.80; range, 0.60–2.50 cm) (p=0.002). 
When considering the TB cutoff  value of  2mg/dl, 29 
of  69 (42.3%) patients in group 1 and 1 of  37 (2.7%) 
in group 2 were  positive  for  jaundice  (p<0.001) 
(Table 1).  Compared with  benign disease (median, 
1.50; range, 0.50–31.40ng/ml), no statistical difference 
(p=0.156) of  serum  CEA  level  was  observed  in 
the  malignant  group  (median,  2.65;  range, 0.00–
210.20ng/ml) (Table 1). Similarly, no considerable bias 
of  serum CA19-9 level was obtained (benign median, 
7.70; range, 2.00–30.10u/ml versus malignant median, 
10.70; range,1.70–36.90u/ml, p=0.154) in the Mann–
Whitney U test (Table 1).
We subsequently performed binary logistic regression 
and pearson correlation analysis to find out those es-
sential factors that were helpful in detection of  malig-
nancy. We found that, age distribution (p=0.002), ab-
dominal-pain (p=0.044) and serum DB level   (p=0.034) 
were   fully  confirmed   as   three   independent  ele-
ments   mostly influencing the final diagnosis (Table 2). 
The other parameters were excluded either because of  
less impact or strong multicollinearity (Table 2). 
 Sig If Removed 
Gender   0.701 
Age 0.002 < 0.001 0.714 
Abdominal pain 0.044 0.032  
Back pain   0.720 
Weight loss   0.346 
Fever   0.649 
Common bile duct   0.755 
Tumor size   0.554 
Total bilirubin   0.182 
Direct bilirubin 0.034 < 0.001 0.769 
Indirect bilirubin   0.177 
CEA1   0.406 
CA19-92   0.776 
Constant 0.001   
 
Table 2.  The statistic assessment on diagnostic utility of clinical and biochemical 
 
parameters  
Variables in the Equation        Variables 
not in the 
Equation(Sig) 
AUC of  the 
ROC Curve
1: CEA equals Carcinoembryonic antigen.
2: CA19-9 equals Carbohydrate antigen19-9
We further built the ROC curve  to  assess  the  diag-
nostic  utility  of   those  candidates  (Fig.1).  The  AUC 
of  age-curve was 0.714 with a 95% confidence interval 
of  0.608 to 0.820. The sensitivity and specificity were 
69.6% and 70.3% respectively with the most efficient 
cutoff  value of  57 years according to the largest Youd-
en index. Similarly, sensitivity of  60.9% and specificity 
of  89.2% were obtained with a cutoff  value of  0.27mg/
dl in ROC curve of  DB (AUC=0.769, 95% confidence 
interval, 0.682 to 0.857). The combination of  three 
variables inferred from the equation was proven to be 
better with a bigger AUC of  0.867(95% confidence in-
terval of0.800 to 0.934).
Discussion
Figure 1. ROC curves of the differential diagnosis utility of age 
distribution, serum direct bilirubin and combination of three 
independent factors concluded by logistic regression 
Figure 1. ROC curves of  the differential diagnosis utility of  age distribution, serum direct bilirubin and combina-
tion of  three independent factors concluded by logistic regression
Diagnosis of  pancreatic head masses remains a tough 
job. In the present study, we systemically evaluated the 
role of  clinical parameters as well as serum bilirubin 
and CEA levels in diagnosing of  pancreatic head can-
cer. We found that age distribution, abdominal pain 
and direct bilirubin were three independent factors that 
could probably improve the detection of  malignancy 
when patients presented with imaging support but nor-
mal CA19-9 level.
The correlation between patients’ age and pancreatic 
cancer was controversial. There was evidence that ad-
vanced age was a significant risk factor of  pancreatic 
cancer among those suspicious16; while there was oppo-
site outcomes provided by Kudo et al that onset age did 
not act as an important factor for developing pancreat-
ic cancer17. Age distribution in our study (p<0.001), as 
same as the former, proved to be one of  the essential 
elements that had the most sharp statistical difference, 
and logistic regression further proved that it (p=0.002, 
removed sig p<0.001) was an independent factor influ-
encing the clinical diagnosis. The ROC curve with an 
AUC of  0.714 demonstrated its medium utility in de-
tecting pancreatic head cancer among normal CA19-9 
group, and it seemed that the age of  57 was the best 
cutoff  point.
69.57% of  malignant carriers and 29.73% of  benign pa-
tients presented after the age of  57 in the study. Com-
pared with a cutoff  age of  50 (93% positive in cancer 
patients) suggested  by Zubarik  R  et  al  as  a  high 
risk  of   pancreatic  malignancy16,  the difference of  
our conclusion mainly might result from different study 
objects(different subpopulation more precisely), and 
different enrolled criteria.
Besides  age,  abdominal  pain  (p=0.023,  logistic  sig 
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p=0.044,  removed  sig p=0.032) appeared as  anoth-
er useful clinical feature in detecting pancreatic head 
cancer. Patients bearing malignant tumors in pancreatic 
head were more likely to present with abdominal pain 
(63.77% versus 45.95% in our study). Although abdom-
inal pain was nonspecific18, it was  the most frequent 
onset symptom in pancreatic  cancer15,19,  and  it  was 
proven  to  have  certain  relation  with  tumor location 
in pancreatic adenocarcinoma20. On the other hand, 
patients with benign lesions did not often appear with 
abdominal pain until it reached considerable size and 
gave rise to the obstruction of  the pancreatico-biliary 
duct21. Therefore, abdominal pain probably correlated 
with malignancy more closely, and this kind of  potential
tendency might be amplified on the condition that pa-
tients’ CA19-9 levels were under 37u/ml.
Sex ratio (p=0.025) and weight-loss (p=0.013) were 
other two clinical factors with  statistical  differences 
in  two  groups  at  first.  However, according  to  the 
subsequent logistic analysis, neither the sex ratio nor the 
weight-loss appeared to be helpful. Although 4 patients 
with fever all belonged to group 1, no significant differ-
ence (p=0.295) was observed in two groups and logistic 
equation further confirmed its helplessness in differ-
ential diagnosis. The same result was also obtained on 
the symptom of  back pain (p=0.604). There were some 
similar findings that above four clinical features were 
not significant risk factors for developing pancreatic 
cancer and they often did not appear until the tumor 
was locally advanced or metastatic16,17,22. Study on cystic 
lesions of  pancreas also revealed that benign tumors of  
pancreas were often asymptomatic at early stage, and 
the symptoms such as back pain would not present until 
adjacent organs were involved22. Hence in accordance 
with our study, sex-ratio, back-pain, fever and weight-
loss were not sufficient enough to distinguish malignan-
cies from benign ones.
Since malignant patients with onset symptom of  jaun-
dice were more likely to have tumors located in the pan-
creatic head20 and jaundice closely correlated with se-
rum bilirubin20, the serum bilirubin level was supposed 
to serve as a helpful diagnostic candidate. In our study, 
the difference of   bilirubin levels  between  malignant 
and benign tumors was substantial (pTB<0.001,pD-
B<0.001,pIB<0.001). Compared with group 2, patients 
in group 1 had extremely higher (>15-fold) concentra-
tions of  direct bilirubin (DB) on average, while total bil-
irubin (TB) and indirect bilirubin (IB) in group 1 were 
more than four times as much as in benign group. In ad-
dition, logistic regression recommended DB (p=0.034, 
removed sig p<0.001) as an independent predictor and 
ROC analysis(AUC=0.769) concluded a reasonable cut-
off  value of  0.27mg/dl with sensitivity of  60.9% and 
specificity of  89.2%. All these results demonstrated 
that DB was a possible important factor among serum 
markers  to screen cancer  patients when the CA19-9 
level is <37u/ml.
The nature of  the correlation between pancreatic can-
cer and bilirubin was not yet clearly defined. Pancreatic 
head masses, which would lead to obstructive jaundice, 
were more likely to present as malignancies in some 
researches10,20,23. The same result was obtained in the 
present study as well. And accordingly, the diameter of  
CBD   was   no   doubt   statistically   different   in   two 
groups  (p=0.002),   which demonstrated the sharp dif-
ference in the extent of  CBD dilation. However on the 
other hand, the sizes of  tumors in both groups were 
almost the same (p=0.599). This interesting contra-
diction revealed that the character of  pancreatic head 
mass, whether benign or not, did play an important role 
in this type of  malignant jaundice. 
This contradiction might be explained as followings. 
Firstly, obstructive jaundice was described in over 90% 
of  patients with pancreatic head carcinoma as a result 
of  either invasion or compression of  the common bile 
duct24; while cystic lesions located in pancreatic head 
were proven to be less likely to cause obstructive jaundice 
for their less progressive growth22. Secondly, compared 
with benign patients or healthy volunteers, pancreatic 
adenocarcinoma  individuals presented considerably 
higher level of  TNF-alpha25  which was demonstrated 
to have toxic effect on cholangiocytes26-28. The suscep-
tibility of  cholangiocytes to TNF-alpha’s cytotoxici-
ty could be enhanced during biliary tract obstruction, 
which would result in severe liver damage and hyper-
bilirubinemia26,27,29. Given these interpretations, hyper-
bilirubinemia  might  more  closely  be  correlated  with 
pancreatic  cancer,  and serum direct bilirubin seemed 
quite sufficient in differential diagnosis of  pancreatic 
head masses with CA19-9<37u/ml
CEA was another serum biomarker of  interest for this 
study because it had been, and would likely continue 
to be, one of  the most extensively used clinical tumor 
markers30-32. Pancreas was proven to be one of  few tis-
sues that can express CEA31, and several studies had 
indicated that CEA was helpful in the diagnosis of  
pancreatic malignancy33-35. However, the present series 
demonstrated that patients in the benign group did not 
have statistically different CEA levels (p=0.156) as that 
of  the cancer group. Thus, CEA had very low accuracy 
in the diagnosis of  pancreatic head  malignancies  in 
patients  with a suspicious  mass  but  normal  CA19-9 
level (<37u/ml). The poor diagnostic utility was prob-
ably due to the fact that the serum CEA level did not 
correlate with its genetic level, but with tumor stage35,36. 
Conclusion
In patients with suspicious pancreatic head masses and 
CA19-9 levels of  <37u/ml, age distribution, abdominal 
pain and direct bilirubin might be useful aid in differ-
entiation between the malignant and the benign. Inter-
estingly, compared with benign tumors, malignancies of  
pancreatic head were more likely to cause obstructive 
jaundice despite of  the sizes of  tumors. CEA, howev-
er, may not be sufficient enough to exclude malignancy. 
Large scale cohort of  forward clinical research studies 
need to be carried out to confirm our findings.
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